Clinical Trial Details


Research Study Summary

A Phase III, multi-center randomized, 24 week, double-blind, parallel group, placebo controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period


The purpose of this research study is to investigate if an experimental drug, R04917838, is effective at reducing negative symptoms of schizophrenia when added to your current antipsychotic treatment.

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176877
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Both Male and Female
Overall Status
24 Weeks
Facility Type


Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information:

Alexian Brothers Hospital Network

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.